BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Market Closed - Euronext Paris 17:30:00 15/05/2024 BST | ||
| 18.36 EUR | +5.54% |
|
| Current month | -0.66% | ||
| 1 month | +2.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 15/05/24 | 18.36 | +5.54% |
| 14/05/24 | 17.39 | -0.01% |
| 13/05/24 | 17.4 | -2.71% |
| 10/05/24 | 17.88 | -2.25% |
| 09/05/24 | 18.29 | -0.97% |
Real-time Euronext Paris
Last update May 15, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| IY17S | |
| ISIN | DE000SV416X4 |
| Date issued | 05/05/2023 |
| Strike | 381.9 $ |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 3.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.69 € |
|---|---|
| Lowest since issue | 3.475 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
- Stock Market
- Certificates
- IY17S Certificat
